PE20201500A1 - Inhibidores de glicolato oxidasa para el tratamiento de enfermedades - Google Patents
Inhibidores de glicolato oxidasa para el tratamiento de enfermedadesInfo
- Publication number
- PE20201500A1 PE20201500A1 PE2020000860A PE2020000860A PE20201500A1 PE 20201500 A1 PE20201500 A1 PE 20201500A1 PE 2020000860 A PE2020000860 A PE 2020000860A PE 2020000860 A PE2020000860 A PE 2020000860A PE 20201500 A1 PE20201500 A1 PE 20201500A1
- Authority
- PE
- Peru
- Prior art keywords
- ring
- diseases
- treatment
- glycolate oxidase
- cycloalkyl
- Prior art date
Links
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 3
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Se refiere a un compuesto de formula (l); donde el anillo C se selecciona de (X) y (W); L es un enlace, CH2, CF2, O, entre otros; el anillo A es cicloalquilo de C3-8, espirocicloalquilo de C8-11, entre otros; el anillo B esta presente o no, cuando el anillo B esta presente es cicloalquilo, heterocicloalquilo, entre otros; R1 es hidrogeno, alquilo, cicloalquilo, entre otros. Dicho compuesto inhibe la enzima glicolato oxidasa (GO), siendo util en el tratamiento y prevencion de enfermedades o trastornos del metabolismo del glioxilato, incluida la hiperoxaluria primaria, que estan asociados con la produccion de cantidades excesivas de oxalato. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762611995P | 2017-12-29 | 2017-12-29 | |
| US201862765313P | 2018-08-20 | 2018-08-20 | |
| PCT/US2018/067784 WO2019133770A2 (en) | 2017-12-29 | 2018-12-28 | Glycolate oxidase inhibitors for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201500A1 true PE20201500A1 (es) | 2020-12-29 |
Family
ID=65234672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000860A PE20201500A1 (es) | 2017-12-29 | 2018-12-28 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11384055B2 (es) |
| EP (1) | EP3732167A2 (es) |
| JP (2) | JP7344878B2 (es) |
| KR (1) | KR20200112860A (es) |
| CN (6) | CN117126152A (es) |
| AR (1) | AR114070A1 (es) |
| AU (1) | AU2018395275A1 (es) |
| BR (1) | BR112020013073A2 (es) |
| CA (1) | CA3086401A1 (es) |
| CL (1) | CL2020001742A1 (es) |
| IL (3) | IL297802A (es) |
| MA (1) | MA51418A (es) |
| MX (6) | MX2020006414A (es) |
| PE (1) | PE20201500A1 (es) |
| SG (1) | SG11202005807QA (es) |
| TW (2) | TW202340155A (es) |
| WO (1) | WO2019133770A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340155A (zh) * | 2017-12-29 | 2023-10-16 | 美商拜奧馬林製藥公司 | 用於疾病治療之乙醇酸酯氧化酶抑制劑 |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| KR20210041564A (ko) * | 2018-07-06 | 2021-04-15 | 오판 바이오테크 인코포레이티드 | 트리아졸 글리콜레이트 옥시다아제 억제제 |
| EP4017490A4 (en) * | 2019-08-22 | 2023-11-22 | Oxalurx, Inc. | COMPOUNDS AND METHODS OF TREATING OXALATE-RELATED DISEASES |
| CA3155577A1 (en) * | 2019-11-01 | 2021-05-06 | GyanRx Sciences, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
| AU2021205916A1 (en) * | 2020-01-08 | 2022-08-25 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022002131A1 (zh) * | 2020-06-30 | 2022-01-06 | 苏州恩华生物医药科技有限公司 | 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
| WO2023170024A1 (en) * | 2022-03-11 | 2023-09-14 | University Of Copenhagen | Camk2 modulators and their use in medicine |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US149223A (en) * | 1874-03-31 | Improvement in axles for vehicles | ||
| DE2860722D1 (en) * | 1977-11-10 | 1981-08-27 | Beecham Group Plc | Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use |
| DE2757929A1 (de) * | 1977-12-24 | 1979-07-05 | Boehringer Sohn Ingelheim | Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung |
| JPS5519292A (en) * | 1978-07-24 | 1980-02-09 | Beecham Group Ltd | Benzopyranotriazoles*their manufacture and medical composition containing them |
| DE2966444D1 (en) | 1978-07-24 | 1984-01-05 | Beecham Group Plc | Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them |
| US4431660A (en) | 1979-06-11 | 1984-02-14 | Merck & Co., Inc. | (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith |
| US4349561A (en) * | 1979-11-05 | 1982-09-14 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| DE3169772D1 (de) * | 1980-01-19 | 1985-05-15 | Beecham Group Plc | Substituted benzopyranotriazoles |
| IL61897A (en) * | 1980-01-19 | 1984-01-31 | Beecham Group Ltd | Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them |
| NZ199139A (en) * | 1980-12-13 | 1985-01-31 | Beecham Group Ltd | Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles |
| US4431652A (en) | 1980-12-29 | 1984-02-14 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
| US4428956A (en) * | 1980-12-29 | 1984-01-31 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
| JPS57158788A (en) * | 1981-03-03 | 1982-09-30 | Beecham Group Ltd | Novel compound, manufacture and medicinal composition containing same |
| WO1993017681A1 (en) * | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| US6962936B2 (en) * | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| JP4075357B2 (ja) | 2001-11-15 | 2008-04-16 | 宇部興産株式会社 | ４，５−ジ置換−１，２，３−トリアゾール及びその製造法 |
| BR0317230A (pt) * | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0603891D0 (en) * | 2006-02-27 | 2006-04-05 | Syngenta Ltd | Novel herbicides |
| WO2011140296A1 (en) * | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
| IN2014DN09348A (es) * | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
| KR101537296B1 (ko) * | 2012-10-26 | 2015-07-17 | 삼성전자 주식회사 | 반도체 나노결정 및 그 제조방법 |
| TW201418242A (zh) | 2012-10-26 | 2014-05-16 | Du Pont | 作為除草劑之經取代的*** |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| US20200262794A1 (en) | 2015-12-07 | 2020-08-20 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| CN105541796B (zh) | 2016-03-03 | 2017-11-14 | 武汉工程大学 | 一种nh‑1,2,3‑***联吡啶化合物的合成方法 |
| CN105669569B (zh) | 2016-03-03 | 2017-12-12 | 武汉工程大学 | 一种nh‑1,2,3‑***化合物的合成方法 |
| TW202340155A (zh) * | 2017-12-29 | 2023-10-16 | 美商拜奧馬林製藥公司 | 用於疾病治療之乙醇酸酯氧化酶抑制劑 |
| BR112021025781A2 (pt) * | 2019-06-19 | 2022-03-03 | Biomarin Pharm Inc | Composto, composição farmacêutica, método de tratamento de uma doença ou transtorno associado com um defeito no metabolismo de glioxilato, método de tratamento de uma doença ou transtorno associado com a enzima glicolato oxidase (go) ou alterações no metabolismo de oxalato e método para inibição da enzima go |
-
2018
- 2018-12-28 TW TW112107812A patent/TW202340155A/zh unknown
- 2018-12-28 CN CN202310936668.6A patent/CN117126152A/zh active Pending
- 2018-12-28 CN CN201880090533.XA patent/CN111788187A/zh active Pending
- 2018-12-28 EP EP18840000.6A patent/EP3732167A2/en active Pending
- 2018-12-28 AR ARP180103914A patent/AR114070A1/es unknown
- 2018-12-28 MX MX2020006414A patent/MX2020006414A/es unknown
- 2018-12-28 TW TW107147699A patent/TWI811282B/zh active
- 2018-12-28 MA MA051418A patent/MA51418A/fr unknown
- 2018-12-28 KR KR1020207022038A patent/KR20200112860A/ko not_active Application Discontinuation
- 2018-12-28 BR BR112020013073-7A patent/BR112020013073A2/pt unknown
- 2018-12-28 CN CN202310936523.6A patent/CN117069712A/zh active Pending
- 2018-12-28 CA CA3086401A patent/CA3086401A1/en active Pending
- 2018-12-28 US US16/958,511 patent/US11384055B2/en active Active
- 2018-12-28 AU AU2018395275A patent/AU2018395275A1/en active Pending
- 2018-12-28 CN CN202310936604.6A patent/CN117024420A/zh active Pending
- 2018-12-28 JP JP2020535997A patent/JP7344878B2/ja active Active
- 2018-12-28 WO PCT/US2018/067784 patent/WO2019133770A2/en active Application Filing
- 2018-12-28 CN CN202310936652.5A patent/CN117069713A/zh active Pending
- 2018-12-28 CN CN202310936618.8A patent/CN117126151A/zh active Pending
- 2018-12-28 IL IL297802A patent/IL297802A/en unknown
- 2018-12-28 SG SG11202005807QA patent/SG11202005807QA/en unknown
- 2018-12-28 IL IL297788A patent/IL297788A/en unknown
- 2018-12-28 PE PE2020000860A patent/PE20201500A1/es unknown
-
2020
- 2020-06-18 IL IL275496A patent/IL275496A/en unknown
- 2020-06-25 CL CL2020001742A patent/CL2020001742A1/es unknown
- 2020-07-13 MX MX2022016463A patent/MX2022016463A/es unknown
- 2020-07-13 MX MX2022016415A patent/MX2022016415A/es unknown
- 2020-07-13 MX MX2022016427A patent/MX2022016427A/es unknown
- 2020-07-13 MX MX2022016434A patent/MX2022016434A/es unknown
- 2020-07-13 MX MX2022016422A patent/MX2022016422A/es unknown
-
2022
- 2022-05-23 US US17/751,136 patent/US20230079913A1/en active Pending
- 2022-05-23 US US17/751,144 patent/US20230089374A1/en active Pending
-
2023
- 2023-08-04 JP JP2023127874A patent/JP2023159181A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201500A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CL2020002277A1 (es) | Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734) | |
| PE20210549A1 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| CU20160111A7 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| DOP2016000094A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4. | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
| PE20171623A1 (es) | Agentes inmunomoduladores | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| ECSP17028459A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| CR20200228A (es) | COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554) | |
| CO6612202A2 (es) | Inhibidores heterparílicos bicíclicos de pde4 | |
| UY36416A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa | |
| CL2018001632A1 (es) | Dendrímeros y formulaciones de los mismos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| AR074467A1 (es) | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| PE20170770A1 (es) | Metodos y composiciones para tratar trastornos relacionados con vih | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2019001618A1 (es) | Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. | |
| CU24560B1 (es) | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |